NECFA
IONS icon

New England Capital Financial Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

New England Capital Financial Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,300
Closed -$53.3K – 402
2023
Q2 		$53.3K Hold
1,300
– – 0.04% 108
2023
Q1 		$46.5K Hold
1,300
– – 0.03% 121
2022
Q4 		$53K Buy
+1,300
New +$54.7K 0.04% 117

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return

New England Capital Financial Advisors's IONS Position: Q3 2023 in Review

New England Capital Financial Advisors sold out of Ionis Pharmaceuticals (IONS) in Q3 2023, closing a stake of 1,300 shares — an estimated $53.3K sold.

New England Capital Financial Advisors first reported a position in IONS in Q4 2022 and held it in 3 quarters. The position peaked at $53.3K in Q2 2023. 311 funds tracked by Wall St. Rank hold IONS as of Q3 2023.

  • New England Capital Financial Advisors reported no remaining Ionis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 1,300 Ionis Pharmaceuticals shares in Q3 2023, an estimated $53.3K.
  • New England Capital Financial Advisors first reported a position in Ionis Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • New England Capital Financial Advisors's Ionis Pharmaceuticals position peaked at $53.3K in Q2 2023.
  • 311 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2023.

Based on New England Capital Financial Advisors's 13F filing for Q3 2023, filed 6 Nov 2023.